KM-023

CAS No. 1097628-00-6

KM-023( —— )

Catalog No. M35996 CAS No. 1097628-00-6

KM-023 is a new second-generation non-nucleoside reverse transcriptase inhibitor for the study of human immunodeficiency virus (HIV) type 1 infection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 358 In Stock
5MG 361 In Stock
10MG 542 In Stock
25MG 870 In Stock
50MG 1163 In Stock
100MG 1562 In Stock
200MG Get Quote In Stock
500MG 3134 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    KM-023
  • Note
    Research use only, not for human use.
  • Brief Description
    KM-023 is a new second-generation non-nucleoside reverse transcriptase inhibitor for the study of human immunodeficiency virus (HIV) type 1 infection.
  • Description
    KM-023 is a new second-generation non-nucleoside reverse transcriptase inhibitor for the study of human immunodeficiency virus (HIV) type 1 infection.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV Protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1097628-00-6
  • Formula Weight
    325.36
  • Molecular Formula
    C18H19N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(=O)(C1=C(C(C)C)C(=O)NC(=O)N1CC)C2=CC(C#N)=CC(C)=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Terameprocol

    Terameprocol is a synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol showed the strongest anti-HIV activity.

  • Nelfinavir

    A potent and orally bioavailable HIV-1 protease inhibitor with Ki of 2 nM.

  • HIV-1 inhibitor 18A

    HIV-1 inhibitor 18A is a novel broad HIV-1 inhibitor that blocks envelope glycoprotein transitions critical for entry.